



AF/3738  
\$ 176

PTO/SB/21 (02-04) (AW 02/2004)

Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission **33**

Application Number	10/082,920
Filing Date	02/25/2002
First Named Inventor	Leonard Pinchuk
Art Unit	3738
Examiner Name	Paul B. Prebilic
Attorney Docket No.	BSI-507US

### ENCLOSURES (Check all that apply)

- |  |  |  |
|--|--|--|
| <input checked="" type="checkbox"/> Fee Transmittal Form<br><input checked="" type="checkbox"/> Fee Attached<br><br><input type="checkbox"/> Amendment/Reply<br><input type="checkbox"/> After Final<br><input type="checkbox"/> Affidavits/Declaration(s)<br><br><input type="checkbox"/> Extension of Time Request<br><br><input type="checkbox"/> Express Abandonment Request<br><br><input type="checkbox"/> Information Disclosure Statement<br><br><input type="checkbox"/> Certified Copy of Priority Document(s)<br><br><input type="checkbox"/> Response to Missing Parts/<br>Incomplete Application<br><br><input type="checkbox"/> Response to Missing Parts under<br>37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s)<br><br><input type="checkbox"/> Licensing-related Papers<br><br><input type="checkbox"/> Petition<br><br><input type="checkbox"/> Petition to Convert to a<br>Provisional Application<br><br><input type="checkbox"/> Power of Attorney, Revocation,<br>Change of Correspondence<br>Address<br><br><input type="checkbox"/> Terminal Disclaimer<br><br><input type="checkbox"/> Request for Refund<br><br><input type="checkbox"/> CD, Number of CD(s) _____ | <input type="checkbox"/> After Allowance Communication<br>to Group<br><br><input type="checkbox"/> Appeal Communication to Board<br>of Appeals and Interferences<br><br><input checked="" type="checkbox"/> Appeal Communication to Group<br>(Appeal Notice, Brief, Reply<br>Brief)<br><br><input type="checkbox"/> Proprietary Information<br><br><input type="checkbox"/> Status Letter<br><br><input type="checkbox"/> Other Enclosure(s) (please<br>identify below): |
|--|--|--|

Remarks:

### SIGNATURE OF APPLICANT, ATTORNEY OR AGENT

Firm or Individual Name	Jonathan H. Spadt	Registration No. (Attorney/Agent)	45,122
Signature			
Date	7/12/2004		

### CERTIFICATE OF TRANSMISSION / MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date:

Typed or printed name	Denise Morgan		
Signature		Date	7/12/2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Office, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, ALEXANDRIA, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



# FEE TRANSMITTAL for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ ) 330

## Complete if Known

Application Number 10/082,920  
Filing Date 2/25/2002  
First Named Inventor Leonard Pinchuk  
Examiner Name Paul B. Preblich  
Art Unit 3738  
Attorney Docket No. BSI-507US

## METHOD OF PAYMENT (check all that apply)

☒ Check ☐ Credit Card ☐ Money Order ☐ Other ☐ None

☒ Deposit Account (use as backup only):

Deposit  
Account  
Number

18-0350

Deposit  
Account  
Name

RatnerPrestia

The Director is authorized to: (check all that apply)

☐ Charge fee(s) indicated below  
☒ Credit any overpayments  
☒ Charge any additional fee(s) or any underpayment of fee(s)  
☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

## FEE CALCULATION

### 1. BASIC FILING FEE

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1001	770	2001	385	Utility filing fee	
1002	340	2002	170	Design filing fee	
1003	530	2003	265	Plant filing fee	
1004	770	2004	385	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	

SUBTOTAL (1)

(\$ ) 0

### 2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

			Extra Claims		Fee from below		Fee Paid
Total Claims		-20**	=	0	X		= 0
Independent Claims		-3**	=	0	X		= 0
Multiple Dependent					X		= 0

Large Entity		Small Entity		Fee Description
Fee Code	Fee (\$)	Fee Code	Fee (\$)	
1202	18	2202	9	Claims in excess of 20
1201	86	2201	43	Independent claims in excess of 3
1203	290	2203	145	Multiple dependent claim, if not paid
1204	86	2204	43	** Reissue independent claims over original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2)

(\$ ) 0

\*\*or number previously paid, if greater; For Reissues, see above

## FEE CALCULATION (continued)

### 3. ADDITIONAL FEES

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for ex parte reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	420	2252	210	Extension for reply within second month	
1253	950	2253	475	Extension for reply within third month	
1254	1,480	2254	740	Extension for reply within fourth month	
1255	2,010	2255	1,005	Extension for reply within fifth month	
1401	330	2401	165	Notice of Appeal	
1402	330	2402	165	Filing a brief in support of an appeal	330.
1403	290	2403	145	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,330	2453	665	Petition to revive - unintentional	
1501	1,330	2501	665	Utility issue fee (or reissue)	
1502	480	2502	240	Design issue fee	
1503	640	2503	320	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	770	2809	385	Filing a submission after final rejection (37 CFR § 1.129(a))	
1810	770	2810	385	For each additional invention to be examined (37 CFR § 1.129(b))	
1801	770	2801	385	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify)

\*Reduced by Basic Filing Fee Paid

SUBTOTAL (3)

(\$ ) 330

## SUBMITTED BY

## Complete (if applicable)

Name (Print/Type)	Jonathan H. Spatt	Registration No. Attorney/Agent)	45,122	Telephone	610-407-0700
Signature				Date	7/12/2004

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No: 10/082,920  
Applicant: Leonard Pinchuk  
Filed: February 25, 2002  
Title: A Method of Treating An Aneurysm  
T.C./A.U.: 3738  
Examiner: Paul B. Prebilic  
Confirmation No.: 3520  
Notice of Appeal Filed: May 14, 2004  
Docket No.: BSI-507US

**APPEAL BRIEF UNDER 37 C.F.R. § 1.192**

Mail Stop Appeal Brief-Patents  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

S I R :

Appellants hereby request consideration and reversal of the Final Rejection dated January 8, 2004, and the Advisory Action dated May 3, 2004, of claims 1-6.

This Brief is presented in the format required by 37 C.F.R. § 1.192, in order to facilitate review by the Board. In compliance with 37 C.F.R. § 1.192(a), this Brief is being filed in triplicate within the time allowed for response to the action from which the Appeal was taken or within two months from the date of the Notice of Appeal, whichever is later.

The fees for filing a Brief in support of an Appeal under 37 C.F.R. § 1.117(c), together with any extension fee required in connection with the filing of this Brief, are provided herewith.

07/16/2004 WABDELRI 00000035 10082920

01 FC:1402 330.00 OP

**I. REAL PARTY IN INTEREST**

The real Party In Interest in this matter is Scimed Life Systems of One Scimed Place; Maple Grove, Minnesota by virtue of an assignment recorded on May 8, 2003, at Reel/Frame 013006/0656.

**II. RELATED APPEALS AND INTERFERENCES**

There are no related appeals or interferences related to the subject matter of this Appeal.

**III. STATUS OF CLAIMS**

Claims 1-6 stand rejected under 35 U.S.C. § 112 ¶1, as failing to comply with the written description requirement. Specifically, the Examiner rejects claim 1, steps (c) and (d) as not inherently described in the application. In particular, the Examiner asserts that there is no original support for: (1) making the restriction means with a restricted diameter greater than the vessel diameter; and (2) trimming the length to a length greater than the aneurysm when the stent is expanded to that maximum diameter.

Claims 1-6 are presented below.

1. A method of treating an aneurysm with a stent-graft comprising the steps of:

- (a) determining the length of the aneurysm;
- (b) determining the diameter of the vessel into which a stent-graft will be placed;
- (c) providing a stent-graft having dilation restriction means for restricting dilation of said stent-graft beyond a maximum diameter which maximum diameter is greater than the vessel diameter of step (b);
- (d) trimming the stent-graft to a length that is greater than the length of the aneurysm when the stent-graft is dilated to its maximum diameter.

2. The method of claim 1 wherein the dilation restriction means of the stent-graft provided in step (c) is comprised of a suture material.
3. The method of claim 2 wherein said suture material is flexible and substantially inelastic.
4. The method of claim 1 wherein said stent is made of woven wires and a suture material is woven through said wires.
5. The method of claim 1 wherein the dilation restriction means of the stent-graft provided in step (c) is comprised of a plurality of sutures spaced along said stent-graft.
6. The method of claim 1 wherein the dilation restriction means of the stent-graft provided in step (c) is comprised of a plurality of sutures located in a plurality of substantially parallel planes which are substantially perpendicular to a longitudinal axis of said stent-graft.

#### **IV. STATUS OF AMENDMENTS**

Applicant's proposed amendments to the specification in the Response dated April 7, 2004, are indicated as entered as of the date of the Advisory Action. No claim amendments are pending.

#### **V. SUMMARY OF INVENTION**

The present invention, unlike anything taught or suggested in any known prior art, is directed to a method of preventing dislodgment of a stent that has been implanted in a vessel for a long period of time. This is accomplished in the claimed method by providing a stent-graft having a dilation restriction means for restricting dilation of the stent-graft beyond a maximum diameter which maximum diameter is greater than the vessel diameter into which the stent-graft will be deployed, and then trimming the stent-graft to a length that is greater than the length of the aneurysm when the stent-graft is dilated to its maximum diameter. This claimed method insures that the stent-graft will not later shorten to a length less than the length of the aneurysm in the vessel and thereby dislodge.

## **VI. ISSUE**

To determine whether applicant's steps (c) and (d) of claim 1 are adequately described in the specification, the Board should consider whether the Examiner applied the correct standard when challenging the presumed adequate written description of applicant's application, that is, has the Examiner overcome the initial burden of presenting by a preponderance of evidence why a person skilled in the art would not recognize in the applicant's disclosure a description of the invention defined by steps (c) and (d) of claim 1.

## **VII. GROUPING OF CLAIMS**

Claims 1-6 stand together.

## **VIII. ARGUMENT**

The following argument sets forth the applicable standard to determine whether claim limitations are adequately described in the written description. Then, this argument demonstrates that the Examiner has applied an incorrect standard and further failed to provide, by a preponderance of the evidence, why one of ordinary skill in the art would not recognize in the applicant's disclosure a description of the invention as defined in the claims. Finally, this argument supports the fact that even if the Examiner were to apply the correct standard and present proper evidence, the applicant has shown that a person of ordinary skill would have understood, at the time the patent application was filed, that the description adequately requires the limitations of steps (c) and (d) of claim 1.

### **A. A claim limitation is adequately disclosed in the written description when a person skilled in the art would recognize in an applicant's disclosure a description of the invention as defined in the claims.**

It is presumed that the written description as filed is adequate unless or until sufficient evidence or reasoning to the contrary has been presented by the Examiner to rebut the presumption. *See, e.g., In re Marzocchi*, 439 F.2d 220, 224, 169 USPQ 367, 370 (CCPA 1971). The Examiner has the initial burden of presenting by a preponderance of evidence why a person skilled in the art would not recognize in an applicant's disclosure a description of the invention defined by the claims. *See, e.g., In re Marzocchi*, 439 F.2d 220, 224, 169 USPQ 367, 370 (CCPA 1971). The

Examiner must have a reasonable basis to challenge the adequacy of applicant's written description. The Examiner's challenge is conducted from the standpoint of one of skill in the art at the time the application was filed. *See, e.g., Wang Labs. v. Toshiba Corp.*, 993 F.2d 858, 865, 26 USPQ2d 1767, 1774 (Fed. Cir. 1993). From this standpoint, the Examiner determines the field of the invention and the level of one of ordinary skill in the art at the time the application was filed. If the Examiner contends that claims are not supported, the Examiner should clearly establish the claim limitation at issue. Then, the Examiner must present a *prima facie* case why a person skilled in the art at the time the application was filed would not have recognized that the inventor was in possession of the invention as claimed in view of the disclosure of the application as filed. *See* MPEP 2163(III)(A).

Generally, to satisfy the written description requirement, a patent specification must describe the claimed invention in sufficient detail that one of ordinary skill in the art can reasonably conclude that the inventor had possession of the claimed invention. *See, e.g., Vas-Cath, Inc. v. Mahurkar*, 935 F.2d 1555, 1563, 19 USPQ2d 1111, 1116 (Fed. Cir. 1991). There is no *in haec verba* requirement in order to satisfy the written description requirement and newly added claim limitations may be supported in the specification through express, implicit, or inherent disclosure. *See* MPEP 2163(I)(B). If an applicant discloses in a patent application a device that inherently performs a function, has a property, operates according to a theory, or has an advantage, the patent application necessarily discloses that function, theory or advantage, even though it says nothing explicit concerning it. If the adequacy of an inherent written description is challenged by an Examiner, the applicant may show inherency by establishing that even though the explicit limitation in a claim "is not present in the written description whose benefit is sought . . . a person of ordinary skill would have understood, at the time the patent application was filed, that the description requires that limitation." *Hyatt v. Boone*, 146 F.3d 1348, 1353, 47 USPQ2d 1128, 1131 (Fed. Cir. 1998).

**B. The Examiner has not overcome the initial burden of presenting by a preponderance of evidence why a person skilled in the art would not recognize in applicant's disclosure a description of steps (c) and (d) of claim 1.**

First, the Examiner has applied the wrong standard in determining that applicant's steps (c) and (d) are not disclosed in applicant's written description. As enunciated above, when an applicant is relying on inherent disclosure, the standard is whether a person of ordinary skill would have understood, at the time the patent application was filed, that the description requires that limitation. In contrast, in the January 8, 2004 Final Office Action, the Examiner's rejection of claim 1, steps (c) and (d), was based on the standard that they "would lack clear antecedent basis from the written description." (Emphasis Added). Furthermore, in the subsequent Advisory Action dated May 3, 2004, the Examiner re-asserted the Section 112 rejection through application of the same incorrect standard, although worded somewhat differently. The Examiner stated, "In particular, . . . there is no original support for making the restricted means with a restricted diameter greater than the vessel diameter and also trimming the length to a length greater than the aneurysm when the stent is expanded to that maximum diameter." (Emphasis Added). The applicant submits that the standard to determine adequacy of the written description for an inherent claim limitation is not "lacking clear antecedent basis" or "no original support," but whether a person of ordinary skill would have understood, at the time the patent application was filed, that the description requires that limitation. Thus, the Examiner has clearly applied the wrong standard.

Moreover, the Examiner stated in the Final Office Action, "Even if it can be shown to be inherent based upon the figures, it [steps (c) and (d) of claim 1] still would lack clear antecedent basis from the written description." This is contrary to established law because drawings alone may provide a written description of the invention as required by Section 112. *See Cooper Cameron Corp. v. Kvaerner Oilfield Prods., Inc.*, 62 USPQ2d 1846 (Fed. Cir. 2002); *see also, Mendenhall v. Cedarapids, Inc.*, 28 USPQ2d 1081 (Fed. Cir. 1993) (in those instances where a visual representation can flesh out words, drawings may be used in the same manner and with the same limitations as the specification).



Second, the Examiner has not overcome the initial burden of presenting by a preponderance of the evidence why a person skilled in the art would not recognize in applicant's disclosure a description of the invention defined by the claims. In fact, the Examiner fails to provide any evidence to support the Section 112 rejection. In the Final Office Action, with respect to steps (c) and (d) of claim 1, the Examiner simply states that the limitations in question lack original support in that there is no clear disclosure of the limitations in the original specification. Similarly, in the Advisory Action, the Examiner concludes steps (c) and (d) are not inherently described, but then again fails to provide any evidentiary support for that conclusion. The Examiner again states, "there is no original support for making the restricted means with a restricted diameter greater than the vessel diameter and also trimming the length to a length greater than the aneurysm when the stent is expanded to that maximum diameter." The Examiner fails to provide any evidence relating to why one skilled in the art would not recognize applicant's claim limitations as described in the specification to support the rejection. Because the Examiner failed to provide any supporting evidence, let alone, a *preponderance of evidence*, the Examiner has clearly failed to show why a person skilled in the art would not recognize in applicant's disclosure a description of the invention as claimed in steps (c) and (d) of claim 1. The applicant submits that the Examiner has therefore failed to overcome the initial burden that applicant's written description is presumed adequate.

**C. Applicant asserts that steps (c) and (d) of claim 1 are described because applicant has shown that a person of ordinary skill would have understood, at the time the patent application was filed, that the description requires that limitation.**

The specification of the patent application teaches to one skilled in the art steps (c) and (d) of claim 1. The method of step (c) requires "providing a stent-graft having dilation restriction means for restricting dilation of said stent-graft beyond a maximum diameter which maximum diameter is greater than the vessel diameter of step (b)." Step (c) has two requirements: 1) that the stent-graft has a dilation restricting means to prevent the stent-graft from dilating past a specific diameter, and 2) that specific diameter is greater than the diameter of the vessel into which the stent-graft is deployed.

In the Summary of the Invention at page 4, lines 11-14, the specification states that it is an object of the invention to provide an endoluminal stent-graft which is resistant to dilation. Further it is an object of the invention to provide an endoluminal stent-graft which is restricted from dilation beyond a selected point. Thus, the first requirement of step (c) would be clearly identified by one skilled in the art from reading the specification.

The second requirement of step (c) would also be identified by one skilled in the art. At page 5, lines 23-33, the specification describes the process by which a physician would determine the resulting length of a stent-graft after dilation due to the shortening of the length of the stent-graft which occurs during dilation. As understood by one of ordinary skill in the art reading the specification, the length of a stent-graft decreases as its diameter increases. Over time, a stent-graft continues to dilate and thereby continues to shorten as depicted in FIGS. 9-10. At lines 27 and 30 of page 7, the specification states, "the doctor would correlate the maximum allowable diameter of the stent with the minimum length of that particular stent needed to bridge the aneurysm." In this manner, the doctor would define a minimum length for the stent-graft that would still prevent the stent-graft from dislodging from the aneurysm as shown in FIG. 11. Therefore, the second requirement of step (c) would also be understood by one skilled in the art reading the specification.

Regarding step (d), the specification provides unambiguous support. At page 7, lines 31-33, it is stated, "That suitable sized and appropriately restricted stent-graft [as determined in step (c)] is then cut to length and deployed in the aneurysm." Although step (d) uses the term "trimming the stent-graft to a length [as determined in step (c)]," the applicant asserts that one skilled in the art would have understood the step of trimming by reading the specification which teaches sizing the stent-graft by cutting it to length.

Even if, for argument sake, the Examiner applied the correct standard and presented, by a preponderance of the evidence, facts sufficient to challenge the presumption of adequacy of applicant's written description as described in detail above, applicant submits that steps (c) and (d) of claim 1 are nonetheless described because applicant has responded to the Examiner's challenge and shown that a

person of ordinary skill would have understood, at the time the patent application was filed, that the description requires those limitations.

In applicant's reply to the Office Action of January 8, 2004, applicant argued as to claim 1, step (c), that one of ordinary skill in the art would understand that it is impossible to deploy a stent-graft into a vessel to repair an aneurysm if the maximum possible diameter of the stent-graft is less than the vessel diameter. Not only would the stent-graft not stay in place, blood would flow around the outside of the graft and into the aneurysm. If the stent did not expand to a diameter greater than the diameter of the vessel, the stent would not work for its intended purpose. That is, the very thing sought to be prevented in bridging the aneurysm with the stent-graft, would occur. This limitation on the maximum diameter of the stent-graft present in step (c) would clearly be known to one skilled in the art reading the disclosure of the present invention.

With regard to claim 1, step (d), which covers the trimming of the stent graft to a particular length prior to deployment, applicant argued this aspect of the trimming step would be clearly known to one skilled in the art reading the invention disclosure. Indeed, if the stent-graft were trimmed to a length *less* than the length of the aneurysm when the stent-graft is dilated to its maximum diameter, the stent-graft would shorten to a length *less* than the length of the aneurysm at full radial dilation and become dislodged. Again, the entire purpose of the invention would be lost, that is, as described throughout the specification and prosecution, to restrict the maximum diameter (radial dilation) to a point that **prevents** shortening of the stent beyond a catastrophic point and subsequent dislodgement. Therefore, this limitation on the trimming step would also clearly be known to one skilled in the art reading the disclosure of the present invention.


Applicant successfully convinced the Examiner of the adequacy of support for step (b) (not discussed herein), but was unable to convince the Examiner that steps (c) and (d) were similarly supported. The Examiner, however, did not provide sufficient rebuttal evidence (as discussed in Section B, *supra*) and maintained the rejection. Therefore, the applicant respectfully asserts that the Examiner is in error.

**E. Conclusion**

The Examiner has applied an incorrect standard in determining the adequacy of applicant's written description. The Examiner challenged the adequacy of applicant's written description and the applicant responded by showing why one of ordinary skill in the art would recognize the claim limitations from applicant's disclosure. The Examiner failed to respond to applicant's showing by presenting a preponderance of evidence, why a person skilled in the art would not recognize, in applicant's disclosure, a description of the invention as defined by steps (c) and (d) of claim 1. The applicant has made clear that the descriptive matter of step (c), providing a stent-graft having dilation restriction means for restricting dilation of said stent-graft beyond a maximum diameter which maximum diameter is greater than the vessel diameter, and step (d), trimming the stent-graft to a length that is greater than the length of the aneurysm when the stent-graft is dilated to its maximum diameter, is supported in the specification and moreover, would be recognized by one of ordinary skill in the art to be part of applicant's disclosure.

The applicant respectfully submits that in view of the above, claims 1-6 are in a condition for allowance and requests that the Board reverse the Examiner's rejection.

Respectfully submitted,



---

Jonathan H. Spadt, Reg. No. 45,122  
Christian M. Bauer, Reg. No. 51,443  
Attorneys for Applicant

Dated: July 12, 2004

P.O. Box 980  
Valley Forge, PA 19482-0980  
(610) 407-0700

The Commissioner for Patents is hereby authorized to charge payment to Deposit Account No. 18-0350 of any fees associated with this communication.

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Appeal Brief-Patents, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on:

July 12, 2004

